UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012

-OR-

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from...to...

Commission File No. 333-36379

PACIFICHEALTH LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE		22-3367588
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

100 Matawan Road, Suite 150
Matawan, NJ		07747
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (732) 739-2900

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files)

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-25 of the Exchange Act) Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 20,871,772 shares of common stock, par value $0.0025, outstanding as of May 3, 2012.

PACIFICHEALTH LABORATORIES, INC.

TABLE OF CONTENTS

---------------------------------

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	3

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

Balance Sheets as of March 31, 2012 and December 31, 2011	4

Statements of Operations for the three months ended March 31, 2012 and 2011	5

Statements of Cash Flows for the three months ended March 31, 2012 and 2011	6

Notes to Financial Statements	7

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS	12

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	14

ITEM 4. CONTROLS AND PROCEDURES	14

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS	14

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	14

ITEM 3. DEFAULTS UPON SENIOR SECURITIES	14

ITEM 4. RESERVED	14

ITEM 5. OTHER INFORMATION	14

ITEM 6. EXHIBITS	15

SIGNATURES	15

Cautionary Note Regarding Forward-Looking Statements

As used herein, unless we otherwise specify, the terms the “Company,” "we," "us," and "our" means PacificHealth Laboratories, Inc.

This Report contains forward-looking statements concerning our financial condition, results of operations and business, including, without limitation, statements pertaining to:

The development, testing, and commercialization of new products and the expansion of markets for our current products;

The receipt of royalty payments from our agreements with business partners;

Implementing aspects of our business plan;

Financing goals and plans;

Our existing cash and whether and how long these funds will be sufficient to fund our operations; and

Our raising of additional capital through future equity financings.

These and other forward-looking statements are primarily in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations". Generally, you can identify these statements because they include phrases such as "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements are only predictions. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy, and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Report on Form 10-Q. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including those stated in this Report. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

We believe it is important to communicate our expectations to our investors. There may be events in the future, however, that we are unable to predict accurately or over which we have no control. Cautionary language in this Report provides examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PACIFICHEALTH LABORATORIES, INC.

BALANCE SHEETS

(UNAUDITED)

ASSETS

	March 31,			December 31,
	2012			2011
Current assets:
Cash and cash equivalents	$	752,900		$	745,904
Other short-term investments		75,000			75,000
Accounts receivable, net		706,409			369,376
Inventories, net		701,338			571,403
Prepaid expenses		105,161			91,479
Total current assets		2,340,808			1,853,162

Property and equipment, net		107,402			26,729

Deposits		10,895			10,895

Total assets	$	2,459,105		$	1,890,786

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Line of credit	$	37,500		$	37,500
Notes payable		20,691			19,679
Accounts payable and accrued expenses (Includes related
party of $19,586 and $32,000, respectively)		1,130,535			546,712
Deferred revenue		61,554			56,170
Total current liabilities		1,250,280			660,061

Stockholders' equity:
Common stock, $.0025 par value; authorized
50,000,000 shares; issued and outstanding:
20,871,772 shares		52,179			52,179
Additional paid-in capital		21,331,268			21,313,319
Accumulated deficit		(20,174,622	)		(20,134,773	)

		1,208,825			1,230,725

Total liabilities and stockholders' equity	$	2,459,105		$	1,890,786

The accompanying notes should be read in conjunction with the financial statements.

PACIFICHEALTH LABORATORIES, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

(UNAUDITED)

	Three Months
	Ended March 31,
	2012			2011
Revenues:
Net product sales	$	1,750,939		$	1,731,611

Cost of goods sold		1,006,769			960,992

Gross profit		744,170			770,619

Operating expenses:
Sales and marketing		196,413			190,431
General and administrative (Includes related party consulting
of $49,145 and $43,000, respectively)		566,243			536,984
Research and development		17,048			14,817
		779,704			742,232

(Loss) income before other (expense) income and
provision for income taxes		(35,534	)		28,387

Other (expense) income:
Other income		-			2,100
Interest income		113			152
Interest expense		(4,428	)		(3,409	)
		(4,315	)		(1,157	)

(Loss) income before provision for income taxes		(39,849	)		27,230

Provision for income taxes		-			-

Net (loss) income	$	(39,849	)	$	27,230

Basic (loss) income per share	$	0.00		$	0.00

Diluted (loss) income per share	$	0.00		$	0.00

Weighted average common shares - basic		20,871,772			16,665,257

Weighted average common shares - diluted		20,871,772			16,833,590

The accompanying notes should be read in conjunction with the financial statements

PACIFICHEALTH LABORATORIES, INC.

STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

(UNAUDITED)


		2012			2011
Cash flows from operating activities:
Net (loss) income	$	(39,849	)	$	27,230
Adjustments to reconcile net (loss) income to net
cash provided by operating activities:
Depreciation		10,260			13,368
Bad debts		3,000			3,000
Equity instrument-based expense		17,949			16,401
Changes in assets and liabilities:
Accounts receivable		(340,033	)		(349,314	)
Inventories		(129,935	)		58,420
Prepaid expenses		(13,682	)		(15,389	)
Accounts payable and accrued expenses (Includes related
party of ($12,414) and $43,000, respectively)		583,823			345,740
Deferred revenue		5,384			1,186
Net cash provided by operating activities		96,917			100,642

Cash flows from investing activities:
Proceeds from sales of other short-term investments		-			25,000
Purchase of property and equipment		(90,933	)		(2,091	)
Net cash (used in) provided by investing activities		(90,933	)		22,909

Cash flows from financing activities:
Repayments on line of credit		-			(12,500	)
Issuances of notes payable		17,478			-
Repayments of notes payable		(16,466	)		(17,457	)
Common stock issued		-			450,000
Net cash provided by financing activities		1,012			420,043

Increase in cash and cash equivalents		6,996			543,594

Cash and cash equivalents, beginning balance		745,904			134,165

Cash and cash equivalents, ending balance	$	752,900		$	677,759


Supplemental disclosures of cash flow information:
Cash paid for interest	$	4,428		$	3,409

Cash paid for income taxes	$	1,400		$	6,937

The accompanying notes should be read in conjunction with the financial statements

PACIFICHEALTH LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

(UNAUDITED)

1. Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the rules and regulations of the SEC. Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. The unaudited financial statements should be read in conjunction with the financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2011.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Actual results may differ from these estimates. The significant estimates and assumptions made by the Company are in the area of revenue recognition, as it relates to customer returns, inventory obsolescence, allowance for doubtful accounts, valuation allowances for deferred tax assets, and valuation of share-based payments issued under Accounting Standards Codification (“ASC”) 718, “Compensation - Stock Compensation”.

2. Revenue Recognition

Revenue is recognized upon the sale of products as they are sold to customers when title to the goods has passed, the price to the customer is fixed and determinable, and collection from the customer is reasonably assured. All sales revenue is recorded on a net basis, net of incentives paid and discounts offered to customers, and excludes sales tax collected from being reported as sales revenue and sales tax remitted from being reported as a cost.

The Company has a sales agreement with GNC, a significant customer of the Company, whereby unsold product is subject to return provisions. In determining revenue recognition for products shipped to this customer, the Company follows the guidance in ASC 605,”Revenue Recognition”. Certain of the products shipped are under a “pay on scan” model and revenue is deferred by the Company until such time as the customer sells through such products to the end consumer. The amount of deferred revenue relating to pay on scan products reflected in the accompanying balance sheets as of March 31, 2012 and December 31, 2011 amounted to $61,554 and $56,170, respectively.

3. Other Short-Term Investments

Excess cash is invested in auction rate securities with long-term maturities, the interest rates of which are reset periodically (typically between 7 and 35 days) through a competitive bidding process often referred to as a "Dutch auction".

Accordingly, the Company has classified such investments as other short-term investments. During the three months ended March 31, 2012, the Company did not redeem any of these investments.

The Company measures fair value utilizing a hierarchy that prioritizes into three levels the components of valuation techniques that are used to measure fair value. The fair value hierarchy gives the highest priority to quoted market prices (unadjusted) in active markets for identical assets or liabilities (Level 1); lower priority to inputs other than quoted prices that are observable for assets or liabilities, either directly or indirectly (Level 2); and the lowest priority to unobservable inputs (Level 3).

The Company has measured these investments as Level 2 inputs.

4. Inventories

Inventories consist of the following:

	March 31,		December 31,
	2012		2011
Raw materials	$	-	$	5,511
Packaging supplies		4,824		1,897
Finished goods		651,322		521,511
Finished goods on consignment		45,192		42,484
	$	701,338	$	571,403

Included above are reserves against finished goods of $36,171 and $37,121, respectively, at March 31, 2012 and December 31, 2011.

5. Property and Equipment

Property and equipment consist of the following:

	March 31,		December 31,
	2012		2011
Furniture and equipment	$	613,949	$	537,655
Molds and dies		131,005		116,366
		744,954		654,021
Less accumulated depreciation		637,552		627,292
	$	107,402	$	26,729

6. Common Stock Issuances and Stock-Based Compensation

The Company accounts for equity instrument issuances for compensation (including common stock, options, and warrants) in accordance with ASC 718. Such equity issuances encompass transactions in which an entity exchanges its equity instruments for goods or services including such transactions in which an entity obtains employee services in share-based payment transactions and issuances of stock options to employees. The Company recorded charges of $17,949 and $16,401, respectively, in the three month periods ended March 31, 2012 and 2011, representing the effect on loss (income) from operations, loss (income) before provision for income taxes and net loss (income).

Employee Compensation

The Company recorded charges of $15,596 and $14,292 during the three months ended March 31, 2012 and 2011, respectively, for previously issued equity instruments to employees.

The Company did not grant any options to employees during the three months ended March 31, 2012 and 2011, respectively.

Non-Employee Compensation

The Company granted no stock options to consultants during the three months ended March 31, 2012 and 2011. The Company recorded charges of $728 and $0 in the three month periods ended March 31, 2012 and 2011, respectively, for previously issued stock options to consultants.

The Company recorded charges of $1,625 and $2,109 in the three month periods ended March 31, 2012 and 2011, respectively, for previously issued warrants to non-employee athlete endorsers.

The Company did not grant any warrants to non-employee athlete endorsers during the three month periods ended March 31, 2012 and 2011.

In summary, compensation charges to operations for the periods presented are as follows:

	Three Months Ended March 31,
	2012		2011
Employee compensation	$	15,596	$	14,292
Non-employee compensation		2,353		2,109
	$	17,949	$	16,401

A summary of employee options activity under the plans as of March 31, 2012 and changes during the three-month period then ended are presented below:

						Weighted-
				Weighted-		Average
				Average		Remaining		Aggregate
				Exercise		Contractual		Intrinsic
Options	Shares			Price		Term (Years)		Value
Balance, January 1, 2012		1,728,500		$	0.25
Granted during the period		-			-
Exercised during the period		-			-
Expired during the period		(20,000	)		2.14
Cancelled during the period		(75,000	)		0.16
Outstanding, March 31, 2012		1,633,500		$	0.23		2.90	$	62,270
Exercisable, March 31, 2012		782,665		$	0.30		2.23	$	26,757

The market value of the Company’s common stock as of March 31, 2012 was $0.21 per share.

As of March 31, 2012, the total fair value of non-vested awards amounted to $80,028. The weighted average remaining period over which such options are expected to be recognized is 2.61 years.

A summary of non-employee options activity under the plans as of March 31, 2012 and changes during the three-month period then ended are presented below:

					Weighted-
			Weighted-		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
Options	Shares		Price		Term (Years)		Value
Balance, January 1, 2012		25,000	$	0.27
Granted during the period		-		-
Exercised during the period		-		-
Expired during the period		-		-
Outstanding, March 31, 2012		25,000	$	0.27		1.63	$	-
Exercisable, March 31, 2012		-		-		-	$	-

As of March 31, 2012, the total fair value of non-vested awards amounted to $2,184. The weighted average remaining period over which such options are expected to be recognized is 0.75 years.

A summary of warrant activity as of March 31, 2012 and changes during the three-month period then ended is presented below:

				Weighted-
				Average		Aggregate
				Exercise		Intrinsic
Warrants	Shares			Price		Value
Balance, January 1, 2012		2,890,500		$	0.31
Granted during the period		-			-
Expired during the period		(12,500	)		0.14
Outstanding, March 31, 2012		2,878,000		$	0.31	$	17,500
Exercisable, March 31, 2012		2,815,500		$	0.31	$	13,125

As of March 31, 2012, the total fair value of non-vested awards amounted to $4,827. The weighted average remaining period over which such options are expected to be recognized is 0.75 years.

7. Income Taxes

The Company has approximately $17,739,000 in Federal and $4,394,000 in state net operating loss carryovers available as of March 31, 2012 that can be used to offset future taxable income in calendar years 2012 through 2032. The net operating loss carryovers begin to expire in the year 2016 through the year 2032. As of March 31, 2012, the Company has fully reserved for these net operating loss carryovers.

ASC 740, “Income Taxes”, clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. It prescribes a threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

The Company has recorded a liability related to uncertain tax positions in the amount of $7,368 and $8,768, respectively, at March 31, 2012 and December 31, 2011 relating to certain states in which the Company is required to file state tax returns as they have effectively established nexus in these states. These amounts have been recorded as a component of accounts payable and accrued expenses on the balance sheet.

The Company’s 2009, 2010 and 2011 Federal and state income tax returns are open for examination.

8. Concentrations

Significant customer sales and vendor inventory purchase concentrations are summarized as follows:

	Net Sales
	Three Months Ended		A/R Balance	A/R Balance
	03/31/12	03/31/11	03/31/12	12/31/11
Customer A	16%	16%	20%	33%
Customer B	11%	*	3%	0%
Customer C	10%	11%	6%	9%
Customer D	*	12%	*	*

	Net Inventory Purchases
	Three Months Ended	A/P Balance	A/P Balance	A/P Balance
	03/31/12	03/31/11	03/31/12	12/31/11
Vendor A	82%	70%	66%	57%
Vendor B	12%	26%	4%	2%

* - Not applicable

9. Line of Credit

In April 2008, the Company obtained a one-year revolving line of credit with a financial institution with an interest rate equal to the Wall Street Journal Prime Rate (3.25% as of March 31, 2012) with a floor of 5.00%. This line is collateralized by the short-term investments. The maximum amount that the Company may borrow is limited to 50% of the value of these short-term investments. The Company renewed this one-year revolving line of credit that now matures on May 21, 2012 in the amount of $50,000. As of both March 31, 2012 and December 31, 2011, the outstanding balance was $37,500. The weighted average interest rate for the three months ended March 31, 2012 and 2011 on this line of credit was 5%.

10. CEO Separation Agreement

The Company entered into a Separation and Release Agreement with a former CEO on January 27, 2010. Under the terms of the agreement, the former CEO agreed to provide consulting services for a period of 90 days following the date of the agreement for which he was entitled to $5,673 per week. During the one-year period commencing on January 11, 2010, the former CEO was entitled to the sum of $295,000, less the sum of consulting fees paid during such period and less any income, wages and/or salary received by him during such period in respect of full-time or substantially full-time employment. The Company also agreed to pay the former CEO $50,000 for relocation costs under certain circumstances, the cost of life insurance premiums during the period in which he provides consulting services, and the cost of health insurance coverage for a period of six months. In the three months ended March 31, 2012 and 2011, the Company recognized $0 and $15,364, respectively, of expense under this Agreement.

11. Consulting Agreements

On February 4, 2011, the Company entered into a consulting agreement with Signal Nutrition LLC (“Signal”), a company controlled by a director of the Company. Under terms of the Agreement, Signal will work with outside researchers, assist in developing new products, and formulate sales and marketing plans for the Company. The Agreement has an indefinite term with an option by either party to terminate the agreement with thirty (30) days notice. The Company will pay Signal a fee of $16,000 per month, commencing March 1, 2011, plus approved expenses during the term of the Agreement. Expense for the three months ended March 31, 2012 and 2011 was $49,145 and $43,000, respectively.

Included in accounts payable and accrued expenses at March 31, 2012 and December 31, 2011 is $19,586 and $32,000, respectively, relating to this agreement.

On April 1, 2012, the Company revised their November 1, 2011 agreement with an outside party to provide social media advisory, consulting, and development services which extended the contract date to December 31, 2013 and increased the monthly payments to $16,700. The Company expensed $41,140 during the three months ended March 31, 2012 prior to the revised agreement. The agreement can be terminated with thirty (30) days notice for any reason starting June 1, 2013 or before that time if the outside party does not meet its obligations as outlined in the agreement.

12. Vendor Agreement

On February 9, 2011, the Company entered into an agreement with its largest vendor whereby extended payment terms were granted to the Company up to 90 days from invoice date and up to a maximum credit limit of $750,000. In the second quarter of 2011, the credit limit was increased to $850,000. Unpaid invoices under this agreement will bear simple interest at an annual rate of 5%, calculated on a per diem basis, during the period commencing 31 days following the invoice date until paid, payable monthly. Additionally, the vendor has an interest in the Company’s accounts receivable. At March 31, 2012, there was approximately $105,000 of available credit under this agreement.

13. Subsequent Event

On April 17, 2012, the Company entered into a licensing agreement with Body Glove International that gives the Company the right to use the Body Glove trademark and other intellectual property rights in connection with the design, manufacture, marketing, distribution and sale of a form of the Company’s 2ND SURGE™ Ultra Energy Gel.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In this Report on Form 10-Q, the terms the “Company,” “we”, “us,” and “our” refer to PacificHealth Laboratories, Inc.

(a)

Introduction

PacificHealth Laboratories is a leading nutrition company that was incorporated in the State of Delaware in April 1995. We focus on the development, marketing and selling of patented premium nutrition tools that enable our consumers to enhance their health and improve their performance. Our principal area of focus is exercise performance and recovery, including optimal weight management. Our products can be marketed without prior Food and Drug Administration (“FDA”) approval under current regulatory guidelines.

We are a sales and marketing driven company that derives value from our own brands that are based on the latest nutrition technology. We will continue to expand on the benefits of our core endurance nutrition products while exploring the latest science in order to introduce cutting edge new brands and products that allow our core endurance athletes to work out and compete more effectively. We will also direct new research and development in the endurance nutrition category to drive product development and consumer communications across both existing and new brands.

Endurance

Our research into factors influencing exercise performance, muscle endurance, and recovery has led to the development and commercialization of a new generation of sports and recovery drinks. The key to our technology is the specific ratio in which protein is combined with carbohydrates. We have received two patents on this technology and over 18 studies have been published demonstrating that products based on this technology can extend endurance, reduce muscle damage, improve rehydration, and accelerate muscle recovery. Our research in exercise performance has led to the introduction and commercialization of a number of products for the aerobic athlete including:

· ENDUROX R4^® Recovery Drink – Introduced in February 1999

· ACCELERADE^TM Sports Drink – Introduced in May 2001

· ACCEL GEL^® Advanced Sports Gel – Introduced in February 2004

· 2ND SURGE^® Ultra Energy Gel – Introduced in March 2011

· ACCEL RECOVER^TM Muscle Recovery Bar – Introduced in March 2011

· ENDUROX^® EXCEL^®Natural Workout Supplement – Introduced in March 1997

· ACCELERADE HYDRO^TM Sports Drink with less calories and sugar – Introduced in June 2008

In the first quarter of 2011, we launched two new products: 2ND SURGE and ACCEL RECOVER. 2ND SURGE is an energy gel that is the first all-natural product specifically formulated to delay the onset of both muscle and brain fatigue. The product’s proprietary formula contains rapidly acting carbohydrates, specific proteins, caffeine and selected antioxidants that are proven to increase the delivery of critical nutrients to brain and muscle cells, maintain metabolic energy needs, inhibit the release of fatigue signals in the brain, and reduce muscle damage, an important trigger for the release of fatigue signals. ACCEL RECOVER is the first bar nutritionally engineered for maximum muscle recovery with a breakthrough formula that incorporates a unique blend of three carbohydrates to rapidly and completely replenish depleted muscle glycogen stores, a proprietary combination of three proteins enriched with glutamine, arginine and leucine, the amino acids that drive the repair and rebuilding of muscle protein and the rapid transport of nutrients to muscles, medium-chain triglycerides that rapidly convert into energy rather than fat and antioxidants to protect muscles from free-radical damage and to regenerate the body’s natural antioxidant pathways.

(b) Results of Operations – Three Months Ended March 31, 2012 and 2011

Revenues for the three-month period ended March 31, 2012 were $1,750,939 as compared to $1,731,611 for the same period in 2011. Included in revenues for the three months ended March 31, 2011 is approximately $24,000 of weight regulation sales which have been discontinued. Therefore, total endurance sales for the quarter ended March 31, 2012 were up 2.5% from the same period in 2011. Increases have come primarily from ENDUROX R4 and 2ND SURGE growth over the prior year.

For the three months ended March 31, 2012, gross profit margin on product sales was 42.5% compared to 44.5% for the three months ended March 31, 2011. Product costs have increased as a result of across the board ingredient price increases, most notably higher protein costs. In addition, increased transportation costs have impacted us. We expect to continue to be challenged by these rising costs throughout 2012.

Sales and marketing (“S & M”) expenses increased $5,982 to $196,413 for the three-month period ended March 31, 2012 from $190,431 for the three-month period ended March 31, 2011. Although no assurances can be given, S & M expenses should remain consistent with 2011 levels although in 2012 the S & M mix will be driven more by our internet and social marketing campaigns.

General and administrative (“G & A”) expenses increased $29,259, or approximately 5.4%, to $566,243 for the three-month period ended March 31, 2012 from $536,984 for the three-month period ended March 31, 2011. Included in G & A in the three month period ended March 31, 2012 and 2011 is approximately $0 and $15,000, respectively, paid to the former CEO in the form of a non-compete clause pursuant to his Separation Agreement. These payments ended under the terms of the Separation Agreement on January 27, 2011. The increase in G & A in the three months ended March 31, 2012 as compared to the same period in 2011 is due primarily to an increase in consultant expenses related to gearing up our Internet and ecommerce presence.

Research and development (“R & D”) expenses were $17,048 for the three month period ended March 31, 2012 compared to $14,817 for the same period in 2011. We will continue to incur R & D expenses for the remainder of 2012 and into 2013 as we invest in science and new products based on this science.

We recorded a net loss of ($39,849), or $0.00 per share (basic and diluted), for the quarter ended March 31, 2012 compared to net income of $27,230, or $0.00 per share (basic and diluted), for the quarter ended March 31, 2011. The net loss in the quarter ended March 31, 2012 as compared to the net income for the same period in 2011 is due primarily to lower gross profit margins and higher G & A expenses. Included in the quarter ended March 31, 2012 is approximately $55,000 in expenses relating to our internet and social marketing campaigns that we did not have in the same period in 2011.

(c) Liquidity and Capital Resources

At March 31, 2012, our current assets exceeded our current liabilities by approximately $1,091,000 with a ratio of current assets to current liabilities of approximately 1.9 to 1. At March 31, 2012, cash on hand was $752,900, an increase of $6,996 from December 31, 2011, primarily as the result of an increase in accounts receivable (net of reserves) of $337,033, an increase in inventory of $129,935 (net of reserves), an increase in prepaid expenses of $13,682, issuances of notes payable of $17,478, repayments of notes payable of $16,466, an increase in accounts payable and accrued expenses of $583,823, and an increase in deferred revenue of $5,384 from December 31, 2011. Also, capital expenditures of $90,933 were made in the first three months of 2012. Accounts receivable increased as 1st quarter 2012 sales were significantly higher than 4th quarter 2011 sales. Inventories increased due to higher anticipated sales in the 2nd quarter of 2012 compared to the 1st quarter of 2012. Accounts payable and accrued expenses increased primarily due to the increase in inventory.

Net cash provided by operating activities for the three months ended March 31, 2012 was $96,917 compared to net cash provided by operating activities for the same period in 2011 of $100,642. Average days’ sales outstanding are approximately 28 days as of March 31, 2012 compared to approximately 31 days at March 31, 2011. Inventories increased in 2012 compared to a decrease in inventories in 2011 due to anticipated increased sales. Accounts payable and accrued expenses increased more in 2012 as compared to 2011 primarily due to the increased inventory as well as due to extended payment terms negotiated with our main inventory suppliers. Historically, we have funded inventory purchases through trade credit and we expect that to continue.

As of March 31, 2012, we had $75,000 invested in auction rate securities that are presented as short-term investments on the balance sheet. We have not redeemed any of these investments in 2012. We have obtained a revolving line of credit with a financial institution with a maturity of May 2012 that will accept these securities as collateral. The maximum amount that we may borrow is limited to 50% of the value of these auction rate securities. As of March 31, 2012 and December 31, 2011, the balance of this line of credit was $37,500. The Company expects to renew this credit facility in May 2012.

Capital expenditures of $90,933 were made in the first three months of 2012 consisting primarily of new websites to enhance our Internet presence and computer software to upgrade back office systems. We have no material commitments for capital expenditures.

(d) Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Per Item 305(e) of Regulation S-K, a smaller reporting company is not required to provide the information required by this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures. Based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of March 31, 2012, the end of the period covered by this Report, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms; that such information is accumulated and disclosed to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure; and that such disclosure controls and procedures are effective.

Changes in internal control over financial reporting. During the quarter ended March 31, 2012, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. RESERVED

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number		Description of Exhibit

31.1*		Rule 13a-14(a) Certification of Chief Executive Officer

31.2*		Rule 13a-14(a) Certification of Chief Financial Officer

32*		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*		The following financial information from PacificHealth Laboratories, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) Balance Sheets (unaudited) at March 31, 2012, and December 31, 2011, (ii) Statements of Operations (unaudited) for the three months ended March 31, 2012 and 2011, (iii) Statements of Cash Flows (unaudited) for the three months ended March 31, 2012 and 2011

* Filed herewith

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PACIFICHEALTH LABORATORIES, INC.

.	By:	/S/ STEPHEN P. KUCHEN
	STEPHEN P. KUCHEN
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

	Date: May 3, 2012

PACIFICHEALTH LABORATORIES INC 10-Q